Adaptive biotechnologies corp ADPT.US Overview Analysis

US StockHealth Care
(Powered by Quartr Logo)

ADPT AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.

ADPT Current Performance

-2.59%

Adaptive biotechnologies corp

0.38%

Avg of Sector

-0.07%

S&P500

Top 10 High Relevance to ADPT

  • VCYT Veracyte inc
    Value 4Trend 3Swing Trading 2Whale Interest 2Dividend 1
    See more

ADPT Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Price of ADPT